Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07716332
NA

Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis

Sponsor: Ron Beloosesky MD

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE. The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.

Official title: Apixaban Versus Enoxaparin for Thromboprophylaxis After Delivery

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2026-07-01

Completion Date

2027-04-01

Last Updated

2026-07-21

Healthy Volunteers

No

Interventions

DRUG

Apixaban

Apixaban. 2.5 mg administered orally twice a day

DRUG

Enoxaparin

Enoxaparin 40 mg (or 60 mg for weight \> 91 kg) administered subcutaneously once a day